F. Hoffmann-La Roche Ltd: Roche awarded WHO prequalification for the cobas® HPV test, increasing access to cervical cancer screening tools in low and lower-middle income countries

Every year, over 600,000 women worldwide are diagnosed with cervical cancer and over 340,000 die from this preventable disease, caused by infection with human papillomavirus (HPV). Nine out of 10 women

Related Keywords

Switzerland ,United States ,Japan ,America ,Loren Kalm ,Sabine Borngr ,Kirti Pandey ,Gerard Tobin ,Nathalie Altermatt ,Birgit Masjost ,Bruno Eschli ,Matt Sause ,Roche Group Media Relations ,Roche Group ,Genentech ,World Health Organization ,Global Access Program ,Roche Global Access Program ,Human Papillomavirus ,Global Access ,Global Access Programto ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Hoffmann ,Oche ,Warded ,Prequalification ,Kobas ,Pest ,Ncreasing ,Access ,Cervical ,Dancer ,Screening ,Tools ,Tower ,Middle ,Income ,Countries ,